by Raynovich Rod | Apr 24, 2013 | BIOgraph, Biopharmaceuticals
Biotech Sector Off All Time Highs This Week-IBB Down 2.5% The biotech melt-up that coincided with the surprising Vertex (VRTX) 60% move on April 19 has run its course and the IBB is now 7 pts off the all time high of $177. Vertex was off 4.75% today. Daily trading...
by Raynovich Rod | Apr 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
A Great Quarter for Many Tools and Diagnostic Stocks The tools and diagnostics sector usually underperforms biopharmaceuticals because the companies are more tethered to deal news and fundamentals. We will review our focus stocks below as Q1 earnings come in. NASDAQ...
by Raynovich Rod | Apr 21, 2013 | BIOgraph
I am at BIO next week and will probably not be posting for several days: 2013 BIO International Convention Here are some of the key sessions: Schedule at a Glance | 2013 BIO International Convention
by Raynovich Rod | Apr 19, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph
Vertex Pharmaceuticals Gives Biotech Sector A Turbo Boost Vertex (VRTX $82), a laggard in the frothy biotech universe rose an astonishing 58% on positive Phase 2 clinical news from its cystic fibrosis drug VX-661. The study showed statistically significant improvement...
by Raynovich Rod | Apr 17, 2013 | Biopharmaceuticals, Macro
Major Sell-Off Early On April 17–Correction is Here with Some Technical Damage Posted 12.15p EDT, Update at 4:56p The rally yesterday was apparently a head fake as a major sell-off resumed today with the NASDAQ down 2.10% and the S&P down 1.7%. The gold free...
by Raynovich Rod | Apr 15, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph, Clinical Diagnostics and Tools, Macro
Gold Crash Spooks Traders-Life Science Stocks Lose Resilience IBB ($166.82) Down 1.6% Rayno Life Science Stocks- Quick Look With NAZ at 2343 We have not made any Rayno Portfolio changes but have added two stocks recently: Genomic Health (GHDX) and Hologic (HOLX) both...
by Raynovich Rod | Apr 12, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, Macro
Biotech and Drug Stocks Remain in the Sweet Spot NAZ Down 0.16% at 3295 at Close A string of market up days was halted today as retail sales and consumer sentiment gave bearish indicators.Commodity stocks were also weak-energy down 1.2%, materials down 1.7%- and there...
by Raynovich Rod | Apr 10, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Blow Through New Highs The Rayno Biopharma stocks continued their run today and some Tools/DX stocks are freshening up. Yesterday we added Hologic (HOLX) as a turnaround/value play and it is up 1.73%. Other Rayno winners in this lagging sector...
by Raynovich Rod | Apr 10, 2013 | Macro
Concern About FED Tightening Reverses Psychology And Becomes Another Reason To Buy Equities QE May End This Summer FED minutes were released early showing concern about exit from $4T inventory of bonds and further effects of QE like the current asset bubble, future...
by Raynovich Rod | Apr 9, 2013 | BIOgraph, Clinical Diagnostics and Tools
Hologic (HOLX) Offers Good Long Term Value We will add Hologic Inc. to our Diagnostics and Tools Portfolio. Prior to its acquisition by Hologic we had GenProbe Inc. on our focus list. Hologic (HOLX $21.70), Market Cap of $5.84B, offers good long term value with a...